Skip to main content

Diabetic Ulcer clinical trials at UCLA

4 research studies open to eligible people

Showing trials for
  • Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

    open to eligible people ages 18-85

    This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.

    Torrance, California and other locations

  • Quasi-Randomized Evaluation of the UCLA Next Day Clinic (NDC)

    open to eligible people ages 18 years and up

    The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions [UVAS] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.

    Los Angeles, California

  • Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

    open to eligible people ages 18 years and up

    This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.

    Torrance, California and other locations

  • Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

    open to eligible people ages 22-90

    The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device at 12 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.

    Los Angeles, California and other locations

Our lead scientists for Diabetic Ulcer research studies include .

Last updated: